Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"2ME2"”.

  1. Evaluation of the Pharmacokinetic-Pharmacodynamic relationship, Metabolism and Plasma Protein Binding of the novel antitumor agent, 2-Methoxyestradiol (2ME2), following oral administration in patients with solid tumors.

    … safety, tolerability and pharmacokinetics of 2ME2 in patients with solid tumors and determine maximum tolerated dose (MTD). The following hypotheses were tested: 1) 2ME2 will be well tolerated in clinic when given orally and will have quantifiable effects on the ex vivo markers of angiogenesis …

    vcu Repository record for Evaluation of the Pharmacokinetic-Pharmacodynamic relationship, Metabolism and Plasma Protein Binding of the novel antitumor agent, 2-Methoxyestradiol (2ME2), following oral administration in patients with solid tumors. (opens in a new tab)

  2. Characterisation of novel anticancer agents in childhood acute lymphoblastic leukaemia

    … were investigated. 2-Methoxyestradiol (2ME2) is a multi-targeted TBA active in various cancer types, yet its efficacy and mechanisms(s) of action in haematological malignancies are not well evaluated. To improve understanding of mechanisms(s) of action and drug resistance, leukaemia …

    unsw Repository record for Characterisation of novel anticancer agents in childhood acute lymphoblastic leukaemia (opens in a new tab)

  3. 2-Methoxyestradiol, a novel pharmacological inhibitor for Angiotensin Type I Receptor

    … of the estrogen metabolite, 2-Methoxyestradiol (2ME2), on AT1R expression.The study used rat liver epithelial cells as the primary cell model to determine the 2ME2 induced cellular signaling, the overall concept was further confirmed in rat aortic smooth muscle cells and further validated in vivo …

    ttu Repository record for 2-Methoxyestradiol, a novel pharmacological inhibitor for Angiotensin Type I Receptor (opens in a new tab)

  4. Inhibition of progestin-induced VEGF in mammary cancer by curcumin and 2-methoxy estradiol and their potential role as anti-angiogenic & chemopreventive compounds

    … root derivative, and 2-methoxyestradiol (2ME2), a natural metabolite of estradiol, effectively inhibit progestin-induced VEGF secretion from breast cancer cells in vitro. Furthermore, curcumin delays progestin-accelerated DMBA-induced tumorigenesis in Sprague-Dawley rats. 2ME2 inhibits …

    missouri Repository record for Inhibition of progestin-induced VEGF in mammary cancer by curcumin and 2-methoxy estradiol and their potential role as anti-angiogenic & chemopreventive compounds (opens in a new tab)

  5. Mechanisms of Neonatal Brain Injury in a Rat Pup Hypoxic-Ischemic Model

    … a activity was inhibited by 2-methoxyestradiol (2ME2,1.5, 15 or 150 mg/kg) or enhanced by dimethyloxalylglycine (DMOG, 250 mg/kg). 2ME2 treatment exhibited dose-dependent neuroprotection by decreasing infarct volume and reducing brain edema at 48 h post HI. The neuroprotection was lost when 2ME2 …

    loma-linda Repository record for Mechanisms of Neonatal Brain Injury in a Rat Pup Hypoxic-Ischemic Model (opens in a new tab)

  6. Endogenous Protection in Subarachnoid Hemorrhage

    … either pharmacologically (2-methoxyestradiol, 2ME2) or genetically in endothelial cells (EC-HIF-1-null). All experiments were performed in a randomized and blinded fashion.We found the following: first, isoflurane postconditioning markedly reduced SAH-induced DCI in wild-type mice: vasospasm …

    wustl Repository record for Endogenous Protection in Subarachnoid Hemorrhage (opens in a new tab)